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There is growing interest in how best to adapt and readapt treatments to individuals to maximize clinical
benefit. In response, adaptive treatment strategies (ATS), which operationalize adaptive, sequential clinical
decision making, have been developed. From a patient’s perspective an ATS is a sequence of treatments, each
individualized to the patient’s evolving health status. From a clinician’s perspective, an ATS is a sequence of
decision rules that input the patient’s current health status and output the next recommended treatment.
Sequential multiple assignment randomized trials (SMART) have been developed to address the sequencing
questions that arise in the development of ATSs, but SMARTs are relatively new in clinical research. This article
provides an introduction to ATSs and SMART designs. This article also discusses the design of SMART pilot
studies to address feasibility concerns, and to prepare investigators for a full-scale SMART. We consider an
example SMART for the development of an ATS in the treatment of pediatric generalized anxiety disorders.
Using the example SMART, we identify and discuss design issues unique to SMARTs that are best addressed in
an external pilot study prior to the full-scale SMART. We also address the question of how many participants
are needed in a SMART pilot study. A properly executed pilot study can be used to effectively address concerns
about acceptability and feasibility in preparation for (that is, prior to) executing a full-scale SMART. Copyright
© 2012 John Wiley & Sons, Ltd.
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1. Introduction
With the establishment of evidence based treatments for many chronic conditions, there is growing
interest and need for research on how to adapt and readapt treatments to maximize clinical benefit. That
is, there is growing interest in developing health interventions that are individualized to the patient and
which respond over time to the needs (successes, benefits) of the patient. In the field of mental health, for
example, the director of the National Institute of Mental Health (NIMH) recognizes the current state of
interventions research: ‘To improve outcomes we will need to [develop treatments which]. . . personalize
care based on individual responses’ [1].
Effective clinical management of chronic conditions (such as psychiatric disorders) often requires
a sequence of treatments, each adapted to individual response, and hence multiple treatment decisions
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throughout the course of an individual’s clinical care. For example, in child and adolescent mental health,
the American Academy of Child and Adolescent Psychiatry practice parameters for pediatric depressive
disorders recommend antidepressants following a nonresponse to initial psychotherapy [2]. Similarly,
for pediatric anxiety disorders, an augmentation strategy of medication is recommended for children
who show partial response to first-line psychotherapy [3]. Sequential treatments, in which treatments are
adapted over time, are often necessary because treatment outcomes are heterogeneous across patients,
treatment goals change over time, and in the long-term it is necessary to balance benefits (e.g., symptom
reduction) with observed and potential risks (e.g., unwanted side-effects, patient burden) [4, 5]. As a
result, clinicians often find themselves implicitly engaging in a sequence of treatments with the goal of
optimizing both short-term and long-term outcomes.
Adaptive treatment strategies (ATSs) [4–7] formalize such sequential clinical decision making. An
ATS individualizes treatment via decision rules that specify whether, how, and when to alter the
intensity, type, or delivery of treatment at critical clinical decisions. Examples of critical decisions
include, which treatment to provide initially, how long to wait for the initial treatment to work, how to
determine whether the initial treatment worked or not, and which treatment to provide next if the initial
treatment is or is not working. Treatments at each critical decision may include medications, behavioral
interventions, or some combination of these two. The following is an example of an ATS following an
initial diagnosis of pediatric generalized anxiety disorder:
ATS 1: ‘First treat with the medication sertraline (SERT) for 12 weeks. If the child has not achieved
an adequate response to initial SERT (at week 12), augment by initiating a combination of
sertraline + individual cognitive behavioral therapy (CBT) for 12 additional weeks; otherwise,
if the child shows adequate response, maintain SERT alone for another 12 weeks’.
ATSs should be explicit; for instance, in ATS1, ‘adequate response’ may be defined as the child
exhibiting a value on a symptom scale beyond a prespecified cut-off (more on this topic in Section 4
below). From the perspective of the child and his/her parent(s), the ATS is a sequence of treatments: for
example, SERT for 12 weeks, followed by CBT for another 12 weeks (assuming an inadequate response
to SERT alone). From the perspective of the clinician, the ATS is a clinical decision rule that guides
treatment both initially and also following an assessment of the 12-week response status. ATSs are also
known as adaptive interventions and dynamic treatment regimes [7–22].
Sequential multiple assignment randomized trials (SMARTs, discussed in more detail below)
have been proposed to facilitate or accelerate the development of ATSs and represent an important
advancement in clinical research methodology [5, 23–25]. SMARTs can be used: (1) to discover which
treatments work together in a sequence to lead to improved outcomes; (2) to investigate the interplay
between trajectories of change in illness and the development of sequences of treatments; (3) to compare
different sequences of medication, behavioral treatments or treatment tactics (e.g., treatment delivery
methods); and (4) to investigate the clinical utility of both biological (e.g., genetic information) and
clinician-observable data for individualizing treatment sequences. A central aim of SMARTs is to inform
the construction of an optimized ATS, that is, to develop the sequence of treatments that lead to optimal
outcomes in the long-term. Furthermore, because at their core SMARTs are concerned with the
identification and use of which treatments work best for whom, when, and under what circumstances,
mental health research that employs SMART designs fits squarely within the domain of comparative
effectiveness research, which is another national research priority [26].
Sequential multiple assignment randomized trials are gaining rapid acceptance in the clinical and
health services research community. The seminal NIMH-funded trials CATIE [27] and STAR*D [28,29]
in schizophrenia and depression, respectively, were early precursors to SMARTs and represent important
trials in terms of encouraging researchers to consider the development of ATSs. In oncology, trials
similar to SMARTs were conducted in the early 1990s [30]; see the work of Thall et al. [22]
for more recent work. In mental health and substance abuse research, a number of SMARTs have
been completed or are currently on-going, including trials in alcohol dependence (D. Oslin, personal
communication), attention deficit hyperactivity disorder (W. Pelham, personal communication), cocaine
and alcohol dependence (J. McKay, personal communication), substance abuse problems in pregnant
women (H. Jones, personal communication), and autism (C. Kasari, personal communication).
Despite their promise, increasing popularity, high quality fit for research in individualized medicine,
and adoption by some clinical trialists, SMARTs are relatively new in clinical research. Because of
their novelty, and because SMARTs represent a departure from the standard two-arm randomized clin-
ical trial, questions remain about the use and execution of SMARTs by clinical investigators. Primary
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among these concerns is the issue of feasibility. Study sections, grant-funding review boards, and other
stakeholders often want to see evidence that the proposed SMART study design is feasible. This includes
showing evidence that investigators have the experience to execute the SMART design properly.
External pilot studies have long been used in all areas of health research to address concerns about
feasibility. The primary aim of this article is to provide guidance on executing a SMART pilot study
in preparation for a full-scale SMART. In Section 2 we review the goals of pilot studies. In Section 3
we review the SMART design, and we introduce a motivating example SMART in pediatric anxiety
disorders. In Section 3, we also review the types of scientific questions that a full-scale SMART can
examine. In Section 4 we propose and discuss design considerations within the context of a pilot study
in preparation for a full-scale SMART. In Section 5, we provide general guidance on how to choose
the sample size for a SMART pilot study. To make ideas concrete, we focus on the pediatric anxiety
disorders example SMART throughout the article; however, all of the main ideas presented in this
manuscript extend readily to SMARTs used to develop and optimize ATSs for other chronic disorders.
2. Pilot studies
Following the lead of a diverse set of researchers, statisticians, and methodologists [31–36], we define a
pilot study as a small-scale version of the larger study with the aim of fine-tuning the study design,
evaluating its feasibility and acceptability, and preparing the research team for a future ‘full scale’
randomized trial. In this manuscript, ‘feasibility’ means both the ability of the investigators to execute
the SMART, and the ability to treat participants with the ATSs that comprise (i.e., that are embedded
in) the SMART (see below). By ‘acceptability’ we mean the tolerability or appropriateness of the ATSs
(including assessment procedures that make up the ATSs, see Section 4 below) being studied from both
the perspective of study participants and clinicians.
There is a distinction in the statistical literature concerning internal versus external pilot studies; the
definition given above (which we use throughout) is consistent with the definition of an external pilot
study. A common aim of internal pilot studies, on the other hand, is to improve sample size calculations
during the execution of the already-developed full-scale trial. In this case, they use the first prespecified
number of subjects to recalculate the sample size needed for the remainder of the full-scale trial. As
such, internal pilot studies are not concerned with examining feasibility and acceptability; for more
information on internal pilot studies, consult the work of Wittes and colleagues [37–39].
A well-designed and executed external pilot study helps answer questions such as: ‘Are we able to
deliver properly the interventions we are proposing to compare?’ ‘What is the level of staff under-
standing and fidelity to the research protocol?’ ‘Are the proposed adaptive interventions acceptable to
participants?’ ‘Should we devise special quality control measures and procedures to improve and
maintain fidelity during the large scale trial?’
Pilot studies also offer the opportunity to fine-tune proposed interventions and may provide
preliminary knowledge about the direction of its effect. Pilot studies can also inform whether a proposed
intervention study is worth pursuing in its current form. For example, if feasibility and acceptability are
found to be lacking beyond what can be achieved by fine-tuning, the outcome of a pilot study may be
that a second pilot or a new study is necessary. Under this definition, the primary role of a pilot study is
not to test hypotheses about the potency of a given intervention, nor to obtain information about effect
sizes with any certainty. For example, this idea is shared in the NIMH’s pilot study program announce-
ment (R34; http://grants.nih.gov/grants/guide/pa-files/PAR-09–173.html), which explicitly states that
‘. . . conducting formal tests of outcomes or attempting to obtain an estimate of an effect size is often
not justified.’
The primary aim of this article is to provide guidance on executing a SMART pilot study in prepa-
ration for a full-scale SMART. Beginning in Section 4, we discuss scientific, statistical, and logistical
issues specific to executing a SMART that should be considered in a SMART pilot. This article does not
provide guidance on executing pilot studies in general; rather, we focus on the unique aspects of SMART
designs. Scientists preparing to execute a randomized trial should also refer to the literature on executing
external pilot studies for pointers on more general uses of pilot studies [34–36].
3. Sequential multiple assignment randomized trials
The overarching aim of a SMART is to inform the construction of an optimized ATS. The key feature
of a SMART is that it allows investigators to evaluate the timing, sequencing, and adaptive selection of
Copyright © 2012 John Wiley & Sons, Ltd. Statist. Med. 2012, 31 1887–1902
1889
D. ALMIRALL ET AL.
treatments in a principled fashion by use of randomized data. In a SMART, participants can move through
multiple stages of treatment; each stage corresponds to a critical decision, and participants are ran-
domized at each stage/critical decision. Randomized treatment options at each critical decision include
appropriate single-component or multicomponent treatment alternatives.
An example of a SMART is shown in Figure 1. This SMART can be used to develop an ATS for the
management of pediatric generalized anxiety disorder involving the medication sertraline (SERT), cog-
nitive behavioral therapy (CBT), and a combination of both (COMB). This SMART provides data that
help investigators address two critical decisions: (1) ‘Which treatment to provide first?’ and (2) ‘Which
treatment to provide to non-responding participants?’ Because the answer to each question may depend
on the answer to the other question, the SMART involves two stages of treatment, one per critical deci-
sion. Participating children are first randomly assigned to either 12-weeks of SERT or 12-weeks of CBT
as first-line treatment. After the end of the initial 12 weeks of treatment, each child’s response to treat-
ment is evaluated and classified as either a treatment responder or treatment nonresponder. This binary
indicator is the primary tailoring variable used as part of the SMART: children who are not responding
at the end of 12 weeks are rerandomized between an augmentation of their initial treatment or a switch
in treatment, whereas children who do respond continue with their initial treatment. As indicated in
Figure 1, the primary outcome could be a longitudinal measure of anxiety over the 48-week trial period.
By using sequenced randomizations, SMARTs ensure that at each critical decision, the groups of par-
ticipants assigned to each of the treatment alternatives are balanced in terms of both observed and unob-
served participant characteristics. This includes time-varying characteristics and outcomes experienced
during prior treatment such as symptom levels, side effects, and adherence.
All SMART designs have multiple ATSs embedded within them. For example, in addition to the ATS
described in the Introduction (ATS 1, sub-group A + B), the example SMART shown in Figure 1 also
includes the following three additional ATSs:
Figure 1. This example SMART can be used to develop an adaptive treatment strategy involving sertraline
medication (SERT), cognitive behavioral therapy (CBT), and their combination (COMB) for the management
of pediatric anxiety disorders.
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ATS 2: First treat with SERT only for 12 weeks. Then, if the child does not respond to initial SERT,
switch to CBT alone for 12 additional weeks; otherwise, if the child responds to initial SERT,
maintain on SERT alone for another 12 weeks (subgroup A + C)
ATS 3: First treat with CBT only for 12 weeks. Then, if the child does not respond to initial CBT,
augment treatment by initiating a combination strategy (COMB) of sertraline + CBT for 12
additional weeks; otherwise, if the child responds to initial CBT, maintain on CBT alone for
another 12 weeks (subgroup D + E).
ATS 4: First treat with CBT only for 12 weeks. Then, if the child does not respond to initial CBT,
switch to SERT medication for 12 additional weeks; otherwise, if the child responds to initial
CBT, maintain on CBT alone for another 12 weeks (subgroup D + F)
The four ATSs embedded in the SMART shown in Figure 1 are also described in Table I. These are
the only ATSs embedded in this example SMART.
A full-scale SMART can be used to evaluate a variety of primary and secondary scientific questions to
inform the development of an optimal ATS. SMARTs are factorial designs in a sequential setting [21];
thus the primary aims usually involve main effects. One example of a primary aim is ‘What is the main
effect of first-line treatment?’ For example, in Figure 1, this involves a comparison of first-stage SERT
versus first-stage CBT (subgroup A+B+C versus subgroup D+E+F). Note that this main effect compa-
rison averages over the second stage treatments. A SMART can also be used to contrast two or more
ATSs. For example, in Figure 1, an investigator may be interested in examining which of the four ATSs
leads to the most rapid reduction in symptoms over the course of 48 weeks because of initial diagnosis.
Because some participants in the SMART simultaneously are consistent with multiple embedded ATSs
(e.g., participants in subgroup A are consistent with both ATS1 and ATS2), specialized methods that
account for the multiple use of subjects are used to estimate and compare mean outcomes under diffe-
rent ATSs [14,15]. A full-scale SMART also provides investigators the opportunity to investigate the use
of time-invariant (e.g., patient characteristics such as baseline severity, demographic variables or genetic
information) and other time-varying (e.g., adherence with treatment) tailoring variables for improving
sequential treatment (these may be the exploratory aims of a SMART). For instance, the example child-
hood anxiety SMART could be used to explore if treatment adherence and treatment satisfaction over the
course of the initial 12 weeks are important predictors of second stage treatment response such that they
may be useful additional tailoring measures. This can be done using standard treatment-by-covariate
moderator analyses of the impact of second-line treatments on subsequent outcomes — for example,
‘Among nonresponders, does adherence during the initial 12 weeks of treatment moderate the impact
of subsequently augmenting versus switching treatments during the next 12 weeks?’— or using more
sophisticated data analytic methods such as dynamic regime marginal structural model estimation [14],
iterative minimization and G-estimation of the structural nested mean model [10, 12, 16], or Q-Learning
([4, 40] for software, see http://methcenter.psu.edu). In other SMARTs, the duration of the first stage
of treatment may differ between trial participants; for example, this may occur when the second stage
Table I. The four adaptive treatment strategies embedded as part of the example SMART design shown in
Figure 1.
Adaptive treatment strategy
Label First stage Primary Second stage Type of Subgroup**
treatment tailoring treatment strategy*
variable
ATS1 SERT Responder SERT Maintain-Augment A + B
Nonresponder SERT+CBT
ATS2 SERT Responder SERT Maintain-Switch A + C
Nonresponder CBT
ATS3 CBT Responder CBT Maintain-Augment D + E
Nonresponder SERT+CBT
ATS4 CBT Responder CBT Maintain-Switch D + F
Nonresponder SERT
*All of the ATSs embedded in the SMART in Figure 1 maintain (or continue) the first-stage treatment as a second-stage
treatment if the subject is an early responder to first-stage treatment.
**These are the subgroups from Figure 1 containing participants who are consistent with the ATS.
Copyright © 2012 John Wiley & Sons, Ltd. Statist. Med. 2012, 31 1887–1902
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begins at an event time (as in the ExTENd trial example below). In such cases, the duration of first-stage
treatment could also be examined in secondary analyses for its potential usefulness as a tailoring vari-
able. Hence, SMARTs are used not only to test treatment options at particular stages of treatment and to
contrast embedded ATSs, but also yield high-quality data to inform the clinical utility of individualizing
treatment using additional tailoring.
Consistent with the overarching aim of a SMART, data analyses associated with these primary
and secondary aims avoid choosing the best treatment at each critical decision point using separate
one-at-a-time optimizations. To appreciate why this is important, consider that a first-line treatment
leading to poorer outcomes in the short-term may lead to better outcomes in the long-term when con-
sidered as part of a whole ATS. For instance, in the SMART in Figure 1, it is possible for first-stage
CBT to lead to poorer (or similar) symptom relief at the end of 12 weeks relative to first-stage SERT;
yet when evaluated at 48 weeks, beginning with CBT results in lower symptoms than beginning with
SERT. This can happen, for example, if the initial CBT sets the stage for a more pronounced response to
COMB among nonresponders in the second stage (say, by priming the individual to take advantage of the
subsequent CBT) than initial SERT. Or to consider another case, suppose that the CBT provided as part
of COMB includes components designed to increase adherence to medication. Here, SERT may be the
better initial treatment when considered part of a sequence; this can happen if initial SERT reveals pre-
scriptive information: initial treatment by SERT may be better than CBT at identifying individuals who
are poor adherers, and thus indicate who needs COMB (which, in our example, includes components to
improve adherence). Other conjectures are possible. The key point here is that developing an ATS by
piecing together the treatments that are best myopically (i.e., work best at the end of each decision point)
may be a suboptimal way to proceed in terms of long-term outcomes.
It is important to understand that the SMART is not an adaptive trial design [41, 42]. Just as the stan-
dard two-arm RCT is a fixed trial design, the SMART is also a fixed trial design that does not change
during the course of the trial. What is adaptive about the SMART are the treatment strategies embed-
ded within the SMART (e.g., ATS1–ATS4, described above). It is conceivable, of course, to conduct a
SMART using an adaptive trial design by allowing some design parameters (e.g., sample size or sample
selection) to vary with interim data; this topic, however, is outside the scope of this article.
Sequential multiple assignment randomized trials can be seen as developmental trials used to con-
struct and optimize an ATS. Following the successful completion of a SMART, the constructed ATS can
be tested against a usual care treatment (or other state-of-the-art intervention) in a standard RCT. In such
a confirmatory trial, participants would be randomly assigned to either the state-of-the-art intervention
or to the SMART-optimized ATS to test which treatment strategy is more effective. SMARTs can also
be sized to have other roles besides that of a developmental trial. For example one could size a SMART
to conduct a comparison of the embedded ATSs; this may be particularly attractive when one of the
embedded ATSs represents ‘usual care.’
4. Considerations to address in a SMART pilot
In this section we discuss nine topics specific to executing a SMART that can be considered in a SMART
pilot. Table II provides examples of issues/concerns that may arise (specific to each topic) and how they
may lead to changes in the full-scale SMART protocol.
4.1. The primary tailoring variable
One area unique to a SMART is the importance placed on tailoring variables. In preparation for a
SMART, a key exercise is to undertake a thorough discussion about the primary tailoring variable.
(Note that in the ATSs embedded within a SMART, the primary tailoring variable is used to adap-
tively determine the next treatment; in contrast, in the SMART design, the primary tailoring variable
determines the set of randomized treatment options.) This involves brainstorming about how to deter-
mine early signs of nonresponse and when this determination should be made. As part of this discussion,
investigators will need to decide how to assess early response/nonresponse (e.g., the Clinical Global
Impression-Improvement Scale (CGI-I) [31]?), and what criterion or cut-score should be used (e.g., less
than 3 on the CGI-I?). Other considerations include: how sensitive is the measure to treatment change?
Is there an established precedent in the literature that can be used to justify the measure as a tailoring
variable? Would the measure be feasible in real-world settings?
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Table II. Feasibility or acceptability issues/concerns and subsequent changes in the full-scale SMART
protocol. Examples are given by topic addressed in Section 4.
Topic Examples of issues discovered in the SMART
pilot
Possible changes to the SMART or in prepara-
tion for the SMART
Primary tailor-
ing variable
A long paper and pencil assessment, more
appropriate for research than for practice, was
used. Mid-way through the pilot, investigators
noticed that it was too long and burdensome
for both study participants and first-stage clini-
cians. This led to missing or delays in items
used to assess early non/responder status and,
as a result, an inability to randomize second-
stage treatment in a timely manner.
A new version of the primary tailoring varia-
ble embedded within the electronic medical
record (EMR), which was more appropriate for
clinical practice, was implemented. Feedback
from attending clinicians in the pilot study was
used to develop the new assessment, which was
tested during the second-half of the pilot study
prior to rolling it out in the full-scale SMART.
Randomization
procedure
A real-time sequentially randomized alloca-
tion procedure was first used. During the pilot,
many nonresponders to first-stage treatment
who were not adherent ended up (by chance) in
the second-stage augmentation arms. Further-
more, there were difficulties in communication
between the attending clinician and study coor-
dinators to obtain second-stage treatment allo-
cation at the end of the 12 week clinic visit,
resulting in some subjects who left the clinic
without an assigned second-stage treatment.
The allocation procedure was modified for the
full-scale SMART to include adherence as a
stratification measure in the second randomiza-
tion. Furthermore, additional steps were taken
to make it easier to obtain treatment allocations
at the end of the 12 week clinic visit based
on early non/responder status; and an auto-
mated reminder from the EMR was added where
second-stage clinicians would be notified that




Children who missed the 12 week clinic
visit but subsequently returned for treatment,
were all classified as nonresponders, and
re-randomized at the time of the post 12-week
visit to second-stage treatment. At the time,
it was intuitive to define the embedded ATSs
this way because investigators thought chil-
dren who missed clinic visits did so because
they were having more difficulties. However,
this led to problems as missed visits were, in
fact, not always related to how poorly the child
was doing.
For the full-scale trial, a different approach was
used whereby children who missed the 12 week
clinic visit were labeled as non/responder based
on fixed rule which involved the last known
non/responder status. This new rule for handling





Investigators piloted a measure of adherence
to first-stage treatment. This measure was to
be examined as a tailoring variable for more
refined treatment tailoring in secondary analy-
ses. Adherence measurements were taken every
6 weeks (hence, by the time children were ready
to move to second-stage treatment, there were
2 adherence measures). However, many parti-
cipants would stop adhering prior to the first
adherence measurement at 6 weeks.
For the full-scale trial, adherence was collected
more frequently. This will allow investigators in
the full scale trial to examine ‘time until nonad-
herence’ as a potential tailoring variable leading





During the pilot study, clinicians noted (quali-
tatively, that is, based on intuition) that fami-
lies of nonresponders who were more difficult
to manage seem to have benefitted more from
switch rather than augmentation. This came up
in pilot study meetings between investigators
and study clinicians. Some clinicians argued
that this was a due to participant dissatisfaction
with first-stage treatment; that is, these fami-
lies were more difficult to manage because they
were not satisfied with first-stage treatment.
In the full-scale trial, satisfaction, preference,
and additional process data was collected
by study coordinators such as tardiness to
clinic visits and number of re-schedules. These
data will be used in secondary, hypothesis-
generating analyses of the full-scale SMART to
determine if it is useful (in conjunction with
other clinical measures) for developing a more
refined ATS.
Copyright © 2012 John Wiley & Sons, Ltd. Statist. Med. 2012, 31 1887–1902
1893







During the course of the SMART pilot, research
staff — not fully understanding the distinction
between the SMART study versus the ATSs
embedded within it — used evaluation assess-
ments to supplement clinician assessments in
the determination of early non/responder status.
SMART quality-control procedures were put in
place to prevent evaluation assessments from







In a small number of cases, psychiatrists
(psychologists) treating with first-stage SERT
(CBT) held-off on labeling cases as nonrespon-
ders to delay a possible switch to CBT (SERT).
Beyond being a violation of the SMART study
protocol, this was possible indication that defi-
ning the embedded ATSs on the basis of
a 12 week early non/response criteria was
not appropriate.
SMART quality-control procedures were
enacted for the full-scale trial to prevent
this from happening. Furthermore, based on
feedback from clinicians that 12 weeks was
insufficient time in first-stage treatment, in
the full-scale trial early non/response criteria
leading to second-stage treatment was defined





During the pilot study, investigators learned that
among nonresponders initially receiving CBT,
subsequent switch to SERT (medication) led
to substantial treatment nonadherence as well
as drop-out. Focus group discussions revealed
that there were parental concerns about med-
ication, in general, and with medicating chil-
dren at this young age, in particular. Parents
reported that there was no time or forum dur-
ing clinic visits where they could bring up these
concerns about medication. The problem was
mainly in the participants who switched from
CBT to SERT, but group discussions revealed
that similar problems were also occurring any-
time SERT was being offered (including as first
stage treatment).
A manualized medical management (MM)
module, successfully used in a previous trial,
was to be included in conjunction with SERT.
MM included a brief clinician-administered
educational intervention (using motivational
enhancement techniques, as well as print mate-
rials) for improving adherence, discussing the
benefits/costs/side effects/rationale for medica-
tion, and a format for families to raise their con-
cerns over medications. The new MM+SERT
(which was to replace SERT) was piloted with
the remaining pilot study participants and later





In the SMART pilot, participants consented
to be part of the study up-front and it was
explained that this meant the participant could
receive one of various treatment sequences.
Focus group discussion revealed that some par-
ticipants did not find second-stage treatments
helpful/acceptable and dropped out of the study
shortly after learning about their second-stage
treatment assignment. Research staff incor-
rectly understood this to mean that participants
were not consenting to the randomly allocated
second-stage treatment. As a result, these par-
ticipants were not followed up for subsequent
outcome assessments.
Consent procedures were revised prior to the
full-scale SMART. A quality control proce-
dure was implemented to remind research staff
that study consent occurs up-front only (even
though a real-time randomized allocation proce-
dure was being used) and that failure to accept
second-stage treatment assignment did not pre-
clude research staff from attempting to obtain
outcome assessments.
In addition to identifying how to assess the tailoring variable, investigators must determine how fre-
quently the tailoring variable needs to be assessed. That is, how often should early response/nonresponse
be evaluated? This will depend in large part on the domain being studied and historical precedent. In our
example in Figure 1, response/nonresponse is assessed at one point in time (12 weeks) and a score62 on
the CGI-I is the criterion. Participants who are not responding at 12 weeks are rerandomized to the next
stage treatment. In this example — which uses a primary tailoring variable fixed at a prespecified number
of weeks after the initiation of first-stage treatment — it is necessary for investigators to operationalize
what they mean by ‘end of 12 weeks’. This is because, as with any study, it is not always feasible to
schedule clinic visits at exactly ‘the end of 12 weeks’ because of scheduling conflicts. Often, for exam-
ple, a prespecified window of time around 12 weeks would be used. Indeed, this issue is not unique to
SMARTs. However, in a SMART the width of the window deserves particular attention because different
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window lengths imply different operationalizations (definitions) of the ATSs, which are embedded in the
SMART. The related issue of how to define the primary tailoring variable when non/responder status is
missing is discussed below.
In other SMARTs, multiple assessments for early response and/or nonresponse can occur and the pri-
mary tailoring variable is a summary of these multiple assessments. Or the primary tailoring variable
may be defined as a ‘time until’ outcome of first-stage treatment. For example, in a SMART concern-
ing alcohol dependence (the ExTENd clinical trial, D. Oslin, personal communication), counts of heavy
drinking days are used to measure response/nonresponse and participants are assessed weekly to ascer-
tain the number of heavy drinking days occurring over the prior week. Here the participant is deemed
to be an early nonresponder as soon as >2 heavy drinking days occur. Note that in the ExTENd exam-
ple, the primary tailoring variable — defined as a ‘time until’ measure — requires more frequent moni-
toring times (compared with a primary tailoring variable assessed at the end of first-stage treatment, as in
Figure 1) adding logistical complexity. The pilot study can be used to examine the feasibility of assessing
and using such a measure.
In other example SMARTs, the primary tailoring variable need not be dichotomous (e.g., it may be
a trichotomous variable measuring responder, nonresponder, and partial responder status). However, the
more complicated the primary tailoring variable, then the more complex the trial design becomes because
the randomized treatment options may differ by values of the primary tailoring variable. In general, the
choice of primary tailoring variable should be driven by a primary, parsimonious scientific question.
Another advantage of parsimony in the choice of primary tailoring variable is that it allows for observed
variability on other measures, which may be useful for building ATSs that are more refined (i.e., which
may offer more individually-tailored treatments) than those embedded in the SMART by design. These
additional measures would be considered in secondary analyses of the data arising from a SMART. That
is, other, possibly more interesting, scientific questions involving more refined tailoring (such as consid-
ering how to tailor treatment using a less coarse/continuous tailoring variable, or such as using adherence
to first-stage treatment to decide how to treat nonresponders in the second-stage) can be addressed as
part of secondary analyses; for more on this topic, see Section 4.4.
The SMART pilot should allow the investigative team ample opportunities to train in applying the
approach for assessing and using the primary tailoring variable, assessing whether the approach is clin-
ically feasible, and refining the measurement of the primary tailoring variable and refining the criterion
for determining early response/nonresponse during the full-scale trial.
4.2. Randomization procedure
In a SMART, participants are randomized at multiple critical decisions over the course of the trial. Inves-
tigators can chose between two randomization procedures: an up-front approach or a real-time approach.
In the up-front approach, participants are randomized at the beginning of the trial to the different ATSs
that are embedded in the SMART design. In our example, this means randomizing participants at baseline
to one of the four ATSs described in Section 2. In the real-time approach, participants are randomized
sequentially at each critical decision point as described in Figure 1. In both approaches, participating
families will be informed during the consent process of the possible treatment sequences to which they
might be randomized. Compared with the up-front approach, the real-time approach has at least one
important advantage: it allows investigators to capitalize on information (including time-varying covari-
ates) available at time of randomization to ensure balance in assigned treatment options at each critical
decision stage. For instance, if we use a real-time approach in our example, the second randomiza-
tion among nonresponders (to initial SERT or initial CBT) can be stratified on adherence to treatment,
symptom severity, or other important outcomes observed during the first 12 weeks of treatment. This
is advantageous because if, by chance, the composition of groups differs by these variables and these
variables are prognostic for subsequent study outcomes, then differences between the groups can be
attributed to these compositional differences as opposed to differences between second stage treatments.
The up-front approach does not afford investigators this level of control over compositional balance.
A SMART pilot study will give the research team’s analyst an opportunity to develop and evaluate the
randomization procedure and check for unanticipated errors.
4.3. Missing the primary tailoring variable
In our example, the primary tailoring variable is response status (responder/nonresponder) at the end
of acute treatment (week 12). Ideally, all participants in a SMART will have a measure of the primary
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tailoring variable available at the end of 12 weeks that can be used to guide subsequent treatment assign-
ments. However, this ideal situation might not hold. That is, the assessment of a given participant’s
response to the first 12 weeks of treatment may be missing, either because the participant dropped-out
of the study prior to week 12, or because the participant was unavailable for the week 12 assessment
(e.g., the participant might be ill or on vacation). The problematic situation for purposes of executing the
SMART is the latter one, in which a participant is unavailable for the 12-week assessment yet returns to
the study at some later point when a decision must be made concerning response/nonresponse status and
next step in treatment.
All randomized trials must contend with missing data, but this problem is unique in SMARTs because
the interventions (e.g., the ATSs) that make up a SMART are adaptive. The critical issue here is how to
manage missingness for purposes of offering/assigning subsequent treatment, as opposed to how to han-
dle missing evaluation outcomes for purposes of data analysis. As in standard randomized trials, the pilot
can be used to prepare and practice low burden approaches that can be used to facilitate the collection of
the missing evaluation outcomes (e.g., via telephone assessments). Beyond this, a satisfactory solution
to the ‘missing tailoring data problem’ (as opposed to ‘missing evaluation data problem’) is one that rec-
ognizes that this type of missingness should be part and parcel of the definition of the ATSs embedded
in the SMART, just as in typical clinical practice the clinician has to decide next treatment when faced
with missed visits. Therefore, the solution to this problem should be guided by what would be achieved
in clinical practice. Clinical investigators should ask ‘How do I treat a patient when s/he returns after a
missed clinic visit and what do I need to know concerning the missed visit to make this decision?’ Inves-
tigators may need to differentiate between excused (e.g., family could not find childcare for younger
siblings) and unexcused missed assessments, how long the participant was missing, how many sessions
the participant attended in the first treatment phase, how well or poorly the participant was doing prior to
missing, or how well the participant is doing when s/he reappears. The actual approach used will depend
on the particular research question(s) being investigated and the types of disorders and treatments being
studied. Consistent with these ideas, the solution to this problem involves having a fixed, prespecified
way to determine subsequent treatment in the presence of a missed clinic visit. This can be operational-
ized in at least two ways in the SMART: First, missingness could be made part of the definition of early
nonresponse. This approach could be taken if in actual practice, a missed clinic visit is clinically viewed
as nonresponse (this is often the case in substance abuse treatment). One way to operationalize this is to
classify all participants with missing response status at any given decision point as nonresponders, then
assign the participant their randomized treatment option at the next clinic visit. This approach could be
labeled ‘nonresponding until proven responding’. The opposite approach, or ‘responding until proven
nonresponding,’ could also be employed whereby a participant missing the responder/nonresponder sta-
tus is classified as a responder for purposes of subsequent treatment assignment. Another option in the
case of a missing 12-week visit is to devise an approach that relies on data that would be readily available
to the clinician in practice, including previous response to treatment and current clinical status up to the
point of missingness to determine the responder status. This option requires investigators to decide how
to summarize the observed history of treatment response, including the decision of how much historical
data to use. A second way to operationalize missingness as part of the ATSs embedded in the SMART is
to treat it separately from non/responder status and offer a separate treatment altogether. This approach
may be more appropriate than the above approach if the second stage treatment options are simply not
feasible for subjects exhibiting this type of missingness. Importantly, no matter what approach is used,
the choice of subsequent treatments in the presence of missingness should be well-specified and fixed
prior to the trial. The SMART pilot will allow the investigative team to train in applying the chosen
approach and assess whether it is clinically feasible and scientifically relevant.
4.4. Other potential tailoring variables
The investigative team must also decide which additional potential tailoring variables should be col-
lected. Potential tailoring variables include both baseline patient characteristics and time-varying mea-
sures (e.g., treatment adherence or side effects) that might be useful in tailoring the treatment to the
patient. In the childhood anxiety example, investigators may want (in the full-scale SMART) to explore
whether patient characteristics and baseline measures might be used to tailor initial treatment, and
whether patient characteristics, baseline measures, and outcomes because of initial treatment (but col-
lected prior to the subsequent critical decision point) may be used to tailor the second treatment. A
time-varying tailoring variable can be measured at a single point (e.g., the week 12 clinic visit) or may
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be a cumulative summary of treatment response up to that point in time. Potential tailoring variables
should be simple, easy to use (minimal burden) in actual clinical practice — for example, short-form
of instruments — and able to be collected by the treating clinician. The SMART pilot can be used to
pilot such instruments, items, or questions under consideration for tailoring. Although these variables
will not impact the full-scale trial (unlike the primary tailoring variable), they could lead to the creation
of new variables useful for tailoring treatment in future studies or found to be important when the data
are analyzed.
The use of tailoring variables represent an important departure from standard randomized trials, even
when designed with an interest in understanding moderators which predict treatment response [44],
because they are rarely considered outcomes to initial treatment, such as symptom, side effect, and
adherence measures, which may predict later outcomes to second-stage treatments. This is one impor-
tant reason why SMARTs more closely mirror clinical practice and will ultimately lead to information
that is more clinically relevant to the practicing clinician.
4.5. Identifying unanticipated tailoring variables
Just as the SMART pilot can be used to practice the measurement of new tailoring variables identi-
fied a priori, as described above, it may also be helpful in identifying unanticipated variables that can
be useful for tailoring treatment and can then be measured in more detail in a full-scale trial. Focus
groups or structured exit interviews scheduled during and after the SMART pilot will likely be helpful
in uncovering new and potentially important tailoring variables. Such focus groups can also be used
with nonclinician members of the treatment team (e.g., research assistants, project coordinators). For
example, in the context of our example SMART, families who are more difficult to schedule frequently,
arrive late to visits, require repeated reminders, rush through paperwork, and more challenging to work
with may benefit more from one treatment over another when compared with families who are highly
compliant and easier to manage.
4.6. Evaluation (or SMART) assessments versus treatment (or ATS) assessments
In a SMART, a clear distinction is made between research assessments for purposes of data analysis
to evaluate the effectiveness of ATSs (data used in evaluation) versus assessments made as part of the
ATS to inform subsequent treatment assignment (data used in tailoring). Indeed, keeping these assess-
ments distinct is not entirely unique to SMARTs; in standard two-arm RCTs it is equally important to
differentiate between information gathered and shared as part of treatment versus information gathered
for purposes of evaluating treatment effectiveness. However, in SMARTs it is important to further high-
light this distinction because of the realistic possibility that ATSs embedded within the SMART could
unknowingly become ill-defined if evaluation data is implicitly or explicitly used in the determination of
early non/response during the conduct of the SMART.
In our example, the week 12 response status is assessed by the treating clinician as part of the ATS
(data used in tailoring). Because the aim of the SMART study is to inform actual clinical practice, it is
acceptable for the week 12 response status (used to inform subsequent treatment randomizations) to be
an unblinded clinician evaluation. However, other assessment measures are also collected at the week 12
visit and are used to determine the effectiveness of treatment(s) (data used in evaluation). The key differ-
ence is that the latter assessments are not part of the embedded ATSs. If possible, it is important to use
blinded independent evaluators (clinicians not involved in the provision of treatment) to collect the out-
come measures that will be used to evaluate the effectiveness of the ATS or its components. It is equally
important to ensure that only data used in tailoring (i.e., as part of the embedded ATSs) is used to deter-
mine subsequent treatment changes. The SMART pilot will provide staff an opportunity to prepare and
practice these assessment methods and strategies for maintaining these two types of assessments sepa-
rate and distinct. Fundamentally, this distinction is about understanding the distinction between SMART
versus the ATSs embedded within the SMART.
4.7. Staff acceptability and fidelity to changes in treatment
A properly executed SMART requires careful staff fidelity to changes in treatment provided over time
as dictated by the study design. This may be challenging because (1) clinical researchers accustomed
to participating in standard randomized trials may have little experience with sequenced treatments
that are an explicit part of the SMART research protocol and (2) following the SMART protocol may
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limit the use of clinical judgment. Prior to a full-scale SMART, a pilot SMART can be used to iden-
tify concerns clinicians may have about the sequence of treatments offered and the assessment of early
response/nonresponse. The pilot can be used to develop training procedures to enhance clinician fidelity
to both the research protocol and treatment strategies and to ensure that the clinical team has the required
training and expertise needed to successfully carryout the SMART. For instance, in our example SMART,
suppose that a child is randomized to receive SERT as first stage treatment and that prior to week 12,
say at week 10, the treating clinician is concerned that the child is worsening and insists that the child be
immediately moved to the next stage of treatment. Is this an indication that the definition and timing of
nonresponse should be revised prior to the full-scale SMART? Do staff members need training in how to
manage these emergent clinical situations in a consistent manner? Can something be learned from this
situation that will refine and improve the sequence of treatments? A SMART pilot can be used to identify
when and where staff flexibility is warranted, to develop fidelity measures for its continued assessment,
and to receive staff feedback about the timing of treatment switches and augmentations.
4.8. Participant concerns about changes in treatment
The SMART pilot can also assess whether treatment changes specified in the SMART are acceptable
to participants and whether the new treatment option(s) being offered are clinically feasible. Understan-
ding participant concerns about the treatment sequences may lead to modifications to enhance its effi-
cacy, acceptability, and feasibility. To inform these concerns, the SMART pilot may include additional
survey items, exit interviews, or focus groups with participants to better understand from their per-
spective what was useful about the sequence of treatments offered, the transitions, and concerns about
acceptability. Questions may include: ‘How was your experience when you transitioned from a psychi-
atrist to a psychologist?’ ‘How was your experience when you participated in the CBT sessions after
having come off your medication?’ ‘Did you find that the concerns you expressed during your sessions
with the psychiatrist were also understood by the psychologist?’ ‘Was the rationale for the treatment
change adequate?’ This information will aid in the execution of the full-scale trial, and also inform treat-
ment delivery and refinement of the treatment strategies. It may also likely lead to additional measures
to investigate for use as tailoring variables.
4.9. Ethical considerations and consent procedures
Sequential multiple assignment randomized trials studies may be more acceptable to participants than
RCTs of a fixed, nonadaptive treatment. With a few exceptions when there are adverse events, in standard
RCTs of fixed nonadaptive treatments there is usually no alternative treatment within the context of the
trial for participants who are not responding well. In contrast, consider the SMART in Figure 1 in which,
if a participant is not responding well then a second treatment is offered. Of course, guarantees cannot be
made prior to a SMART, that a change or augmentation in treatment (among first-stage nonresponders)
will necessarily result in improved outcome; however, in a SMART such changes or augmentations
are examined (and could possibly lead to improved outcomes), whereas in fixed-treatment RCTs this is
usually not an alternative. Furthermore, as in Figure 1, a SMART can involve potentially less burdensome
maintenance or step-down treatment options for responding participants.
From the investigator’s point of view, participants in a SMART are randomized to a number of pre-
specified ATSs (see Table I). From the study participant’s point of view, they are offered a sequence
of treatments over time. A participant who is randomized to ATS1 in the SMART in Figure 1, for
example, may receive either the treatment sequence (SERT, SERT) or the treatment sequence (SERT,
SERT+CBT), depending on their early non/response status. Because interventions offered to SMART
participants are treatment sequences — rather than fixed nonadaptive treatments, as in most standard
RCTs — this aspect of the SMART design may require consent procedures or language different from
those used in a standard RCT. A SMART pilot study can be used to practice these changes in the language
typically used in standard RCT consent forms.
Rerandomization does not imply that reconsent is necessary. As described in Section 4.2, the actual
allocation procedure used may be one that performs the randomizations up-front or in real-time (sequen-
tially). Regardless of the allocation procedure used, SMART participants provide consent up-front to
be part of the entire study and to be assigned to one of the embedded ATSs (and therefore receive one
of the embedded treatment sequences), just as in a standard RCT participants consent up-front to be
part of the study and to be assigned to one of the fixed treatments. A key part of this, of course, is that
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participants have a clear understanding (as part of the up-front consent procedures) of the types of treat-
ment sequences which may be offered during the course of the SMART. Another key part of this is that
investigators understand that a SMART is not a combination/packaging of separate substudies, one per
randomization; rather, a SMART is itself one study with multiple randomizations.
Indeed, reconsenting SMART participants at the second stage may conflate second-stage treatment
drop-out with study consent and have unintended consequences in terms of study drop-out. A SMART
participant may, in fact, not find second-stage treatments acceptable/helpful and as a consequence drop-
out of treatment; this does not mean the SMART participant drops out of the study. This is no different
from a participant in a standard RCT who stops attending CBT sessions after week 5, for example, but
continues to provide outcome assessments (that is, a participant who is a treatment drop-out but not a
study drop-out). The problem with reconsenting SMART participants prior to second-stage treatment
initiation is that — not only is it unnecessary, as described above — it may have the unintended con-
sequence of encouraging study drop-out (leading to missing outcomes) among participants who would
otherwise just have been treatment drop-outs (and possibly continued to provide outcome assessments).
The SMART pilot study can be further used to ensure that study consent is done up-front rather than
sequentially to avoid these concerns.
5. How many participants are necessary for a SMART pilot?
As discussed above, the primary aim of a pilot study is to examine the feasibility of carrying out a future
larger-scale trial, rather than examining the clinical impact of a proposed set of treatments. Correspon-
dingly, the sample size for a SMART pilot study should be based on a feasibility aim, rather than on
detecting an effect size.
To ensure that the investigative team can assess feasibility is to ensure that sufficient number of par-
ticipants appear in all of the subgroups. One way to accomplish this goal is to size the pilot study so
that with fixed probability k, at least m participantswill fall into the nonresponder subgroups B and E in
Figure 1. More formally, the total sample size N can be chosen such that
Pr .MB >m and ME >m/ > k; (1)
where the probability is over repeated pilots of size N , and MB and ME are random variables denot-
ing the number of subjects who fall into nonresponder subgroup B and E, respectively. Assuming that







.1Rj i / for j D B, E; (2)
where Rj i is a dummy indicator which equals 1 if subject i is a responder and 0 if subject i
is a nonresponder. (To ensure approximately equal numbers of participants at each randomization
during the execution of both the pilot and full-scale SMART, investigators may consider permuted-
block randomizations (i.e., AABB-AB-BA-BAAB-. . . ) or more sophisticated minimization allocation
procedures during the conduct of a SMART.) Note that the random variable Vj D
PN=2
iD1 .1Rj i / has a
binomial distribution of sizeN  DN=2 with probability qj , which is the true (unknown) rate of nonres-
ponse to first-stage treatment j . For simplicity (and to be conservative, see below), we further assume
q D qB D qE (equal rates of nonresponse to either first-stage treatment option) so that display (1) is
equivalent to
Pr .V > 2m/2 > k; (3)
where V has a binomial distribution of sizeN  with probability q. Note that subgroups B and C will have
the same number of subjects, as will subgroups E and F, which is why it suffices to focus on subgroups
B and E alone rather than all four nonresponder subgroups. Furthermore, we focus on just the nonre-
sponder subgroups B and E because in practice — with nonresponse rates in the typical range of 35%
to 65% for SMARTs — if nonresponder subgroups B and E contain at least m participants with high
probability, then so will subgroups A and D, respectively; intuitively, this is because responders are not
rerandomized and therefore not further split.
Three steps are required to use display (3) to determine sample size for the pilot study: First, inves-
tigators supply m, a guess at the common nonresponse rate q, and the desired k (say 80% or 90%).
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Table III. The table shows sample sizes required for piloting SMART studies of the type shown in Figure 1.
N is chosen such that with probability k and early nonresponse rate q, a minimum number of participants m
will fall into the nonresponder subgroups B and E (and therefore C and F) in Figure 1.
q
0.35 0.40 0.45 0.50 0.55 0.60 0.65
k D 0:80
mD 2 42 36 32 28 26 22 20
mD 3 56 48 42 38 34 30 28
mD 4 70 60 52 46 42 38 34
mD 5 82 72 62 56 50 46 42
k D 0:85
mD 2 44 38 34 30 26 24 22
mD 3 58 50 44 40 36 32 28
mD 4 72 62 54 48 44 40 36
mD 5 86 74 66 58 52 48 42
k D 0:90
mD 2 48 40 36 32 28 26 22
mD 3 62 54 46 42 38 34 30
mD 4 76 66 58 52 46 42 38
mD 5 90 78 68 60 54 50 44
Second, binomial cumulative distribution functions of different sizes (in increasing order, beginning
with N  D1) with probability qare evaluated (upper tail) at the quantile 2m. This produces a list of non-
decreasing probabilities. Third, choose N  corresponding to the first (the smallest) probability larger
than k, and then set N D 2N . These calculations are easily accomplished using any statistical software
package. An R [45] function, which performs these calculations, is available for download on the Penn
State University Methodology Center website http://methcenter.psu.edu.
Table III shows suggested values ofN for values of k D 0:80; 0:85; 0:90,mD 2; 3; 4; 5, and q varying
from 0.35 to 0.65 As an example, suppose that the investigative team agrees that mD 3 children in one
of the small nonresponder subgroups is a sufficient number to ensure familiarity with the research pro-
tocol, treatment delivery, identify potential problems, and to address the concerns described in Section 4
above. Suppose the team would like to see this happen in the pilot with kD90% probability. If the team
expects a nonresponse rate of qD50% at the end of week 12, then a pilot study for the SMART in
Figure 1 would require approximately 42 participants. The key variable needed is the estimated
non-response rate; this can be estimated based on existing studies in the relevant topic area.
The nonresponse rate q is unknown prior to a SMART pilot. Although the investigators may be be
able to find somewhat similar studies with somewhat similar treatments and participants, it is likely that
the participants and the first stage treatments were not identical to those in previous studies. Thus, it may
be useful to use a value of q smaller than the actual guess so thatN is chosen conservatively. In addition,
in the calculations above we assume the nonresponse rate q is identical for both first-line treatments. In
practice, it is likely this assumption will not hold (indeed, investigators may hypothesize that one of the
first-line treatments will lead to better short-term outcomes). In this case, we recommend investigators
set q to the smaller of the two anticipated nonresponse rates; again this is recommended to be conserva-
tive in the choice of sample size for the pilot. Furthermore, as in any study (pilot or full), it is useful to
inflate N by a guess of the study drop-out/attrition rate. For instance, in the example above, if the team
expects an overall 10% study drop-out/attrition rate by the end of the study, then the pilot study sample
size should be 47D 42=.1 0:10/ instead of 42.
6. Summary
Adaptive treatment strategies hold much promise in operationalizing and informing the type of adap-
tive, sequential treatment decisions made to address chronic conditions in ‘real-world’ clinical settings.
SMARTs have been developed explicitly for the purpose of developing such ATSs. A small number
of SMARTs have been designed, completed or are currently being used in clinical research. Despite
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this, SMARTs are still new to many researchers and some questions remain concerning how to design
SMARTs appropriately. In this article, we presented a number of design considerations, unique to
SMARTs, which are best addressed within the context of a small, but useful, pilot study in prepara-
tion for a full-scale SMART. To motivate and illustrate these considerations, we discussed an example
SMART that addresses how to treat children and adolescents with anxiety disorder using medication,
CBT, and/or the combination of both (including how to treat them following nonresponse to an initial
first-line treatment). This article can be a useful guide to clinical trial investigators who are interested in
planning a SMART study to develop or optimize an ATS.
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